A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Official Title
-----------------
A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities

Conditions
-----------------
Overweight, Obesity

Intervention / Treatment
-----------------
* Drug: LY3502970
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Are native Chinese males or females Have had a stable body weight for the 3 months prior to randomization (less than 5% body weight change) and body mass index of ≥ 30.0 kilograms per square meter (kg/m²) or between 27.0 up to 30.0 kg/m² with at least 1 of the following weight-related comorbidities including Hypertension, Dyslipidemia, Cardiovascular disease, Obstructive sleep apnea Exclusion Criteria: Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus Have used or intend to use any prescription or over-the-counter medications or traditional Chinese treatments within 3 months prior to screening, exception of medications for the treatment of concurrent medical conditions with a stable dose Have known allergies to GLP-1RAs, LY3502970, related compounds, any components of the formulation, or have a history of significant atopy Are overweight or have obesity induced by other endocrinological disorders, diagnosed monogenetic, or syndromic forms of obesity Have or plan to have a surgical, endoscopic or device-based treatment for obesity Have a history or presence of psychiatric disorder, a moderately severe or severe depression status, or a significantly risk for suicide Have a history of acute or chronic pancreatitis Have a known self or family history of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma Have other acute, chronic, or uncontrolled medical conditions, vital organ failure or abnormal laboratory value in the judgment of the investigator would make the participant inappropriate for entry into this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY3502970<br>LY3502970 administered orally | Drug: LY3502970<br>* Administered orally.<br>|
| Placebo Comparator: Placebo<br>Placebo administered orally | Drug: Placebo<br>* Administered orally.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module | Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 | PK: Cmax of LY3502970 | Predose on Day 1 up to 116 (Cohort 1) & 172 (Cohort 2) Days postdose | 
| PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 hour Time Point (AUC0-24) of LY3502970 | PK: AUC0-24 of LY3502970 | Predose on Day 1 up to 116 (Cohort 1) & 172 (Cohort 2) Days postdose | 
| Pharmacodynamics (PD): Change From Baseline in Body Weight | PD: Change From Baseline in Body Weight | Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2) | 
| PD: Change From Baseline in Body Mass Index | PD: Change From Baseline in Body Mass Index | Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2) | 
| PD: Change From Baseline in Waist Circumference | PD: Change From Baseline in Waist Circumference | Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2) | 
| PD: Change From Baseline in Fasting Plasma Glucose | PD: Change From Baseline in Fasting Plasma Glucose | Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety and Tolerability, Chinese, LY3502970